Mitoxantrone, Cytosine Arabinoside, and VP-16 in 36 Patients with Relapsed and Refractory Acute Myeloid Leukemia

Hartmut Link; M. Freund; H. Diedrich; H. Wilke; J. Austein; Michael Henke; H. Wandt; E. Fackler-Schwalbe; G. Schlimok; Rüdiger Hoffmann; A. Calavrezos; H. Poliwoda

doi:10.1007/978-3-642-74643-7_60

JOURNAL ARTICLE

Mitoxantrone, Cytosine Arabinoside, and VP-16 in 36 Patients with Relapsed and Refractory Acute Myeloid Leukemia

Hartmut Link M. Freund H. Diedrich H. Wilke J. Austein Michael Henke H. Wandt E. Fackler-Schwalbe G. Schlimok Rüdiger Hoffmann A. Calavrezos H. Poliwoda

Year: 1990 Journal: Hämatologie und Bluttransfusion Vol: 33 Pages: 322-325 Publisher: Springer Nature

DOI: 10.1007/978-3-642-74643-7_60

Get Full-Text PDF Get Analytical Report

Keywords:

Mitoxantrone Mucositis Medicine Gastroenterology Internal medicine Nausea Refractory (planetary science) Myeloid leukemia Etoposide Vomiting Cytarabine Regimen Neutropenia Surgery Idarubicin Toxicity Chemotherapy

Metrics

Cited By

5.91

FWCI (Field Weighted Citation Impact)

Refs

0.93

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Acute Myeloid Leukemia Research

Health Sciences → Medicine → Hematology

Neutropenia and Cancer Infections

Health Sciences → Medicine → Oncology

Multiple Myeloma Research and Treatments

Health Sciences → Medicine → Hematology

Mitoxantrone, Cytosine Arabinoside, and VP-16 in 36 Patients with Relapsed and Refractory Acute Myeloid Leukemia

Metrics

Citation History

Topics

Related Documents

Mitoxantrone, Cytosine Arabinoside and VP-16 (MAV) for De Novo Acute Myeloid Leukemia: A Pilot Study

Sequential intermediate‐dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia

Mitoxantrone and Standard Dose Cytosine Arabinoside Therapy in Refractory or Relapsed Acute Leukemia

Idarubicin, Cytosine Arabinoside and Etoposide for Relapsed or Refractory Acute Myeloid Leukemia

Etoposide (VP-16) and cytosine-arabinoside (ARA-C) combination for secondary and relapsed acute myeloid leukemia (AML)